| abstract |
The invention relates to the use of R- alpha -lipoic acid and/or S- alpha -lipoic acid and/or one of its physiologically biocompatible salts to reduce appetite and/or body weight, at a preferred daily dose of between 10 mg and 10 g of the free acid form. Recommended single doses are between 10 mg and 5 g of either alpha -lipoic acid variant and are administered orally especially to patients with a body mass index (BMI) > 25 kg/m<2>, preferably in the form of a nutritional supplement as part of an antiobesity therapy. |